ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1220

How Are Flares Reported in Long-term Gout Clinical Trials? A Content Analysis of Randomized Controlled Trials

Sarah Stewart1, Amy Tallon 2, William Taylor 3, Angelo Gaffo 4 and Nicola Dalbeth 2, 1University of Auckland, Auckland, Auckland, New Zealand, 2University of Auckland, Auckland, New Zealand, 3University of Otago, Otago, New Zealand, 4University of Alabama at Birmingham, Birmingham, AL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: clinical trials and randomized trials, gout

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Prevention of gout flares is a central concern to patients with gout.  There are many potential ways that gout flares could be reported in long-term clinical trials. The aim of this study was to analyse methods used to measure and report gout flare outcomes in long-term randomized controlled trials (RCTs).

Methods: A systematic search of electronic databases, supplemented with hand-searching of relevant references lists, was conducted. Articles were included if they were RCTs or articles reporting on analyses of RCT data (i.e. open label extension studies) and reported the impact of an intervention on the prevention of flares in people with gout. The modified Jadad scale was used to assess quality. Gout flare data relating to protocols, outcomes and reporting methods were extracted and synthesised separately for studies of anti-inflammatory prophylaxis and urate lowering/other long term therapy.

Results: A total of 38 articles were included, with 10 reporting outcomes for anti-inflammatory prophylaxis and 28 for urate lowering/other long term therapy. The overall quality score of all articles was good. However, there was marked heterogeneity across trials in gout flare-related entry criteria, flare definitions, data capture methods, reporting methods and time periods used to report gout flares. Anti-inflammatory prophylaxis studies used multiple methods to report gout flare outcomes (mean (SD) 4.3 (2.5) methods/article), while the majority of urate lowering/other long term therapy studies used a single method to report gout flare outcomes. The most common reporting method was the proportion of patients with at least one gout flare (n = 29 articles), followed by the mean number of gout flares per patient (n = 18 articles) (Table). Only studies of anti-inflammatory prophylaxis therapy reported flare duration or pain (Table).

Conclusion: There is wide variation in methods used to measure and report gout flare outcomes in long-term RCTs. Studies of anti-inflammatory prophylaxis interventions generally report a range of flare characteristics, including incidence, number of flares, flare duration, and pain intensity. In contrast, studies of urate lowering/other long term therapy report limited data, mostly the proportion of participants experiencing flare.  These findings support the development of standardized methods to measure and report gout flare outcomes that reflect the burden of flares for studies in which gout flare prevention is an outcome of interest.


Table_ACR


Disclosure: S. Stewart, None; A. Tallon, None; W. Taylor, None; A. Gaffo, Amgen, 2; N. Dalbeth, Abbvie, 5, 8, 9, Amgen, 2, AMGEN, 2, AstraZeneca, 2, 5, 8, 9, Dyve, 5, 8, 9, Dyve BioSciences, 5, Hengrui, 5, 8, 9, Horiaon, 5, 8, Horizon, 5, 8, 9, Janssen, 5, 8, 9, Kowa, 5, 8, 9, Pfizer, 5, 8, 9.

To cite this abstract in AMA style:

Stewart S, Tallon A, Taylor W, Gaffo A, Dalbeth N. How Are Flares Reported in Long-term Gout Clinical Trials? A Content Analysis of Randomized Controlled Trials [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/how-are-flares-reported-in-long-term-gout-clinical-trials-a-content-analysis-of-randomized-controlled-trials/. Accessed April 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-are-flares-reported-in-long-term-gout-clinical-trials-a-content-analysis-of-randomized-controlled-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.